
Chinese General Practice ›› 2023, Vol. 26 ›› Issue (36): 4514-4520.DOI: 10.12114/j.issn.1007-9572.2023.0095
Special Issue: 肿瘤最新文章合辑; 消化系统疾病最新文章合辑
• Article • Previous Articles Next Articles
Received:2023-01-15
Revised:2023-06-20
Published:2023-12-20
Online:2023-07-19
Contact:
ZHU Hong
通讯作者:
朱红
作者简介:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2023.0095
| 指标 | 计算公式 |
|---|---|
| APRI | (AST/ASTULN)×100/PLT |
| FIB-4 | (年龄×AST)/PLT×(ALT1/2) |
| GPR | GGT/GGTULN×100/PLT |
| S-Index | 1 000×GGT/(PLT×ALB2) |
| NLR | NE/LY |
| PLR | PLT/LY |
| FAR | FIB/ALB |
| LMR | LY/MO |
| NrLR | NE×GGT/LY |
| SIRI | MO×NE/LY |
| SII | PLT×NE/LY |
| PNI | ALB+5×LY |
| ALRI | AST/LY |
| AAR | AST/ALT |
| ANRI | AST/NE |
Table 1 Formulas for the calculation of 15 serologically derived indicators
| 指标 | 计算公式 |
|---|---|
| APRI | (AST/ASTULN)×100/PLT |
| FIB-4 | (年龄×AST)/PLT×(ALT1/2) |
| GPR | GGT/GGTULN×100/PLT |
| S-Index | 1 000×GGT/(PLT×ALB2) |
| NLR | NE/LY |
| PLR | PLT/LY |
| FAR | FIB/ALB |
| LMR | LY/MO |
| NrLR | NE×GGT/LY |
| SIRI | MO×NE/LY |
| SII | PLT×NE/LY |
| PNI | ALB+5×LY |
| ALRI | AST/LY |
| AAR | AST/ALT |
| ANRI | AST/NE |
| 组别 | 例数 | 性别(男/女) | 年龄≥60岁〔例(%)〕 | 乙肝病史〔例(%)〕 | 肝硬化〔例(%)〕 | AFP>45 ng/mL 〔例(%)〕 | TB>20.5 μmol/L 〔例(%)〕 | ALB<35 g/L 〔例(%)〕 | ALT>40 U/L 〔例(%)〕 | AST>40 U/L 〔例(%)〕 | ALP>125 U/L 〔例(%)〕 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MVI阳性 | 108 | 94/14 | 30(27.8) | 94(87.0) | 68(63.0) | 68(63.0) | 29(26.7) | 94(87.0) | 60(55.6) | 67(62.0) | 48(44.4) |
| MVI阴性 | 100 | 81/19 | 31(31.0) | 88(88.0) | 71(71.0) | 43(43.0) | 28(28.0) | 86(86.0) | 52(52.0) | 56(56.0) | 30(30.0) |
| χ2值 | 1.418 | 0.26 | 0.044 | 1.513 | 8.315 | 0.034 | 0.048 | 0.264 | 0.783 | 4.622 | |
| P值 | 0.234 | 0.610 | 0.834 | 0.219 | 0.004 | 0.853 | 0.827 | 0.607 | 0.376 | 0.032 | |
| 组别 | GGT>50 U/L 〔例(%)〕 | INR>1.185 〔例(%)〕 | PT延长〔例(%)〕 | FIB>3.03 g/L 〔例(%)〕 | WBC> 7.1×109/L 〔例(%)〕 | NE>4.735 ×109/L 〔例(%)〕 | MO>0.545 ×109/L 〔例(%)〕 | PLT> 155.5×109/L 〔例(%)〕 | 肿瘤直径>7.05 cm 〔例(%)〕 | 肿瘤数目>1个〔例(%)〕 | |
| MVI阳性 | 82(76.0) | 17(15.7) | 10(9.3) | 67(62.0) | 37(34.2) | 30(27.8) | 30(27.8) | 66(61.1) | 54(50.0) | 34(31.5) | |
| MVI阴性 | 69(69.0) | 12(12.0) | 6(6.0) | 50(50.0) | 17(17.0) | 11(11.0) | 17(17.0) | 46(46.0) | 15(15.0) | 16(16.0) | |
| χ2值 | 1.252 | 0.606 | 0.777 | 3.057 | 8.047 | 9.235 | 3.448 | 4.771 | 28.692 | 6.815 | |
| P值 | 0.263 | 0.436 | 0.378 | 0.080 | 0.005 | 0.002 | 0.063 | 0.029 | <0.001 | 0.009 |
Table 2 Comparison of baseline characteristics of MVI-positive and MVI-negative patients in the model group
| 组别 | 例数 | 性别(男/女) | 年龄≥60岁〔例(%)〕 | 乙肝病史〔例(%)〕 | 肝硬化〔例(%)〕 | AFP>45 ng/mL 〔例(%)〕 | TB>20.5 μmol/L 〔例(%)〕 | ALB<35 g/L 〔例(%)〕 | ALT>40 U/L 〔例(%)〕 | AST>40 U/L 〔例(%)〕 | ALP>125 U/L 〔例(%)〕 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MVI阳性 | 108 | 94/14 | 30(27.8) | 94(87.0) | 68(63.0) | 68(63.0) | 29(26.7) | 94(87.0) | 60(55.6) | 67(62.0) | 48(44.4) |
| MVI阴性 | 100 | 81/19 | 31(31.0) | 88(88.0) | 71(71.0) | 43(43.0) | 28(28.0) | 86(86.0) | 52(52.0) | 56(56.0) | 30(30.0) |
| χ2值 | 1.418 | 0.26 | 0.044 | 1.513 | 8.315 | 0.034 | 0.048 | 0.264 | 0.783 | 4.622 | |
| P值 | 0.234 | 0.610 | 0.834 | 0.219 | 0.004 | 0.853 | 0.827 | 0.607 | 0.376 | 0.032 | |
| 组别 | GGT>50 U/L 〔例(%)〕 | INR>1.185 〔例(%)〕 | PT延长〔例(%)〕 | FIB>3.03 g/L 〔例(%)〕 | WBC> 7.1×109/L 〔例(%)〕 | NE>4.735 ×109/L 〔例(%)〕 | MO>0.545 ×109/L 〔例(%)〕 | PLT> 155.5×109/L 〔例(%)〕 | 肿瘤直径>7.05 cm 〔例(%)〕 | 肿瘤数目>1个〔例(%)〕 | |
| MVI阳性 | 82(76.0) | 17(15.7) | 10(9.3) | 67(62.0) | 37(34.2) | 30(27.8) | 30(27.8) | 66(61.1) | 54(50.0) | 34(31.5) | |
| MVI阴性 | 69(69.0) | 12(12.0) | 6(6.0) | 50(50.0) | 17(17.0) | 11(11.0) | 17(17.0) | 46(46.0) | 15(15.0) | 16(16.0) | |
| χ2值 | 1.252 | 0.606 | 0.777 | 3.057 | 8.047 | 9.235 | 3.448 | 4.771 | 28.692 | 6.815 | |
| P值 | 0.263 | 0.436 | 0.378 | 0.080 | 0.005 | 0.002 | 0.063 | 0.029 | <0.001 | 0.009 |
| 变量 | β | SE | Wald χ2值 | OR(95%CI) | P值 |
|---|---|---|---|---|---|
| WBC>7.1×109/L | 1.146 | 0.450 | 6.475 | 3.144(1.301,7.598) | 0.011 |
| 肿瘤直径>7.05 cm | 1.344 | 0.398 | 11.399 | 3.836(1.758,8.372) | 0.001 |
| S-Index>0.097 | 1.152 | 0.576 | 4.006 | 3.165(1.024,9.779) | 0.040 |
| AAR>0.879 | 0.764 | 0.359 | 4.527 | 2.146(1.062,4.337) | 0.030 |
| ANRI>24.074 | 1.018 | 0.437 | 5.422 | 2.769(1.175,6.526) | 0.020 |
Table 3 Multivariate Logistic regression analysis of MVI in patients with HCC
| 变量 | β | SE | Wald χ2值 | OR(95%CI) | P值 |
|---|---|---|---|---|---|
| WBC>7.1×109/L | 1.146 | 0.450 | 6.475 | 3.144(1.301,7.598) | 0.011 |
| 肿瘤直径>7.05 cm | 1.344 | 0.398 | 11.399 | 3.836(1.758,8.372) | 0.001 |
| S-Index>0.097 | 1.152 | 0.576 | 4.006 | 3.165(1.024,9.779) | 0.040 |
| AAR>0.879 | 0.764 | 0.359 | 4.527 | 2.146(1.062,4.337) | 0.030 |
| ANRI>24.074 | 1.018 | 0.437 | 5.422 | 2.769(1.175,6.526) | 0.020 |
| 指标 | 模型组 | 验证组 |
|---|---|---|
| 一致性指数(95%CI) | 0.800(0.739,0.861) | 0.755(0.641,0.868) |
| 截断值(分) | 174 | 174 |
| 灵敏度(%) | 90 | 78 |
| 特异度(%) | 61 | 71 |
| 阳性预测值(%) | 71 | 76 |
| 阴性预测值(%) | 85 | 74 |
| 阳性似然比 | 2.30 | 2.73 |
| 阴性似然比 | 0.17 | 0.31 |
Table 4 Accuracy of prediction model in predicting MVI
| 指标 | 模型组 | 验证组 |
|---|---|---|
| 一致性指数(95%CI) | 0.800(0.739,0.861) | 0.755(0.641,0.868) |
| 截断值(分) | 174 | 174 |
| 灵敏度(%) | 90 | 78 |
| 特异度(%) | 61 | 71 |
| 阳性预测值(%) | 71 | 76 |
| 阴性预测值(%) | 85 | 74 |
| 阳性似然比 | 2.30 | 2.73 |
| 阴性似然比 | 0.17 | 0.31 |
| [1] |
|
| [2] |
|
| [3] |
蔡雪红,陈巍,陈世杰,等. 肝细胞癌术前预测微血管侵犯的研究进展[J]. 中南医学科学杂志,2022,50(3):462-465. DOI:10.15972/j.cnki.43-1509/r.2022.03.040.
|
| [4] |
|
| [5] |
|
| [6] |
|
| [7] |
|
| [8] |
邓家仲,荚卫东. 肝细胞癌微血管侵犯危险因素分析及术前预测列线图模型构建[J]. 中国普通外科杂志,2021,30(7):772-779. DOI:10.7659/j.issn.1005-6947.2021.07.003.
|
| [9] |
|
| [10] |
|
| [11] |
|
| [12] |
姚岚清,陈钟. 原发性肝细胞肝癌微血管侵犯的术前预测及其模型的建立[J]. 中国肿瘤外科杂志,2021,13(1):5-11. DOI:10.3969/j.issn.1674-4136.2021.01.002.
|
| [13] |
|
| [14] |
|
| [15] |
|
| [16] |
|
| [17] |
|
| [18] |
王丽艳,孔凡刚. 肝病患者血清中AST/ALT比值的临床意义研究[J]. 中西医结合心血管病电子杂志,2020,8(30):97-98. DOI:10.16282/j.cnki.cn11-9336/r.2020.30.074.
|
| [19] |
|
| [20] |
|
| [21] |
邹伟婕,陈立,黄学卿,等. 天冬氨酸转氨酶与中性粒细胞比值对肝癌患者TACE治疗预后的影响[J]. 介入放射学杂志,2017,26(8):705-711. DOI:10.3969/j.issn.1008-794X.2017.08.010.
|
| [1] | AN Yanhong, WANG Shidong, LI Xiaoran, GUO Jiayang, WANG Zhe, SHA Peilin, MENG Yijun, LI Xiaoxuan, SHI Xue, YU Zexing, XIAO Yonghua. Study on Risk Factors and Nomogram Prediction Model for Diabetic Kidney Disease: Based on Contrast-enhanced Ultrasound Technology [J]. Chinese General Practice, 2026, 29(21): 2995-3003. |
| [2] | SONG Zhenzhen, CHEN Yang, WANG Jiwen, LIU Huishan, SHEN Simeng, SUN Ying, CHEN Xing. Study of Maternal Risk Factors Associated with Neonatal Asphyxia in Late Preterm and Term Infants [J]. Chinese General Practice, 2026, 29(20): 2874-2878. |
| [3] | YANG Xiaofeng, LI Xianwen, WU Yanfeng, ZHANG Qian, CHEN Juan, ZHAO Fengjiao. Association of Serum Vascular Endothelial Cadherin Levels with the Risk of Post-stroke Cognitive Impairment in Patients with Acute Ischemic Stroke [J]. Chinese General Practice, 2026, 29(20): 2867-2873. |
| [4] | ZHAO Huili, LU Lina, ZHUO Ya, WANG Xin. Clinical Characteristics and Risk Factors for Recurrence of Cryptogenic Organizing Pneumonia [J]. Chinese General Practice, 2026, 29(19): 2648-2655. |
| [5] | ZHENG Renkuo, HUA Fei. The Correlation between Metabolic Dysfunction-associated Steatotic Liver Disease and Papillary Thyroid Carcinoma [J]. Chinese General Practice, 2026, 29(15): 2029-2036. |
| [6] | ZHEN Rui, GU Xufang, GAO Shengwei, ZHANG Bowen, REN Zhenjuan, YANG Ruixuan. Burden of Cardiovascular Diseases Attributable to Metabolic Risk Factors in China 1990—2021 and Projected Trends from 2022 to 2035 [J]. Chinese General Practice, 2026, 29(15): 2077-2083. |
| [7] | HU Jiaqi, LI Duan, FANG Hao, FAN Xingying, DU Wei, ZHOU Hanni. Study on Predictive Model of Non-genetic Risk Factors for Hyperuricemia in a Physical Examination Cohort [J]. Chinese General Practice, 2026, 29(10): 1324-1333. |
| [8] | Chinese Rehabilitation Medicine Association Community Rehabilitation Working Committee. Expert Consensus on Perioperative Nutritional Management for Liver Cancer Based on the Enhanced Recovery after Surgery Concept (2025) [J]. Chinese General Practice, 2026, 29(08): 953-964. |
| [9] | LEI Yingying, ZHENG Siying, WANG Wenxin, JIANG Hong. Prevalence Trend and Prediction of Hypertensive Heart Disease in the World and China from 1990 to 2021 [J]. Chinese General Practice, 2026, 29(05): 641-648. |
| [10] | WANG Biyou, GAO Ying, YOU Junfang, LIU Li, ZHANG Qing, SU Haiyan. Canonical Correlation Analysis of Lipid Ratios and Inflammatory Markers in Individuals at Risk of Cardiovascular Disease [J]. Chinese General Practice, 2025, 28(33): 4132-4139. |
| [11] | LIU Mingbo, HE Xinye, YANG Xiaohong, WANG Zengwu. Interpretation of Report on Cardiovascular Health and Diseases in China 2024 [J]. Chinese General Practice, 2025, 28(32): 3989-4008. |
| [12] | XU Baichuan, WANG Yan, ZHANG Peng, LI Yiting, LIU Feilai, XIE Yang. Research and Analysis of Screening Tools for Chronic Obstructive Pulmonary Disease Comorbidity Lung Cancer [J]. Chinese General Practice, 2025, 28(30): 3847-3852. |
| [13] | SHAO Xiaoying, SHAO Jie, ZHU Yan, SHAO Jinling, SHANG Ling, WU Zhenlian, ZHAO Yu, ZHANG Jiacai. Analysis of the Current Status of Iron Deficiency and Factors Affecting Iron Deficiency Anemia among Children Aged 6-36 Months in Guizhou Province [J]. Chinese General Practice, 2025, 28(27): 3368-3374. |
| [14] | ZHOU Qian, WU Xiaomin, WANG Baohua, YAN Ruohan, YU Miao, WU Jing. Study on Nomogram Prediction Model for Risk of Gastric Cancer [J]. Chinese General Practice, 2025, 28(23): 2870-2877. |
| [15] | ZHAO Xiaoqing, GUO Tongtong, ZHANG Xinyi, LI Linhong, ZHANG Ya, JI Lihong, DONG Zhiwei, GAO Qianqian, CAI Weiqing, ZHENG Wengui, JING Qi. Construction and Validation of a Risk Prediction Model for Cognitive Impairment in Community-dwelling Older Adults [J]. Chinese General Practice, 2025, 28(22): 2776-2783. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||